De-extinction startup Colossal Biosciences is reportedly in discussions to raise new capital, potentially valuing the company between $20 billion and $30 billion. This represents a significant increase from its previous valuation.
The report indicates that Colossal Biosciences is aiming to double or triple its prior valuation through this funding round. The specific details of the fundraising, such as the amount being sought and potential investors, were not disclosed in the source material.
Colossal Biosciences focuses on de-extinction efforts – attempting to bring extinct species back to life using genetic engineering. While the company’s work is scientifically complex, it has attracted considerable attention and investment due to its ambitious goals. The increased valuation reflects investor confidence in the potential of this emerging field and Colossal Biosciences' position within it.
We don't rate truth. We strip the spin and show you which perspectives covered the story. You decide.
Read the original coverage
💬 Comments
📜 Comment Policy